Allogeneic Cytokine-induced killer cell therapy (Stanford University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAllogeneic Cytokine-induced killer cell therapy (Stanford University)

Drug Alias NameAllogeneic CIK

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesAnemia +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesStanford University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesStanford University

Active IndicationsN/A

Inactive IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesAnemia +[5]

Other Information

ATC CodeN/A